| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Theravance Biopharma, Inc. (TBPH) has 11 insiders with recent SEC Form 4 filings, including 6 buys and 8 sells. TBPH is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.65M | $27.37M | - | |
| VP | 355.3K | $5.89M | - | |
| CFO | 336.8K | $5.58M | - | |
| VP | 242.4K | $4.02M | -13,314 | |
| VP | 201.0K | $3.33M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2017 | Pasqualone Frank | SVP, Chief Comm Ops Officer | Buy | 4,000 | $26.34 | $105,358.80 | +1.9% | |
| Aug 11, 2017 | Malkiel Burton G | Director | Buy | 30,000 | $24.59 | $737,670.00 | +92.1% | |
| Aug 11, 2017 | Winningham Rick E64 | Chief Executive Officer | Buy | 10,000 | $24.50 | $245,000.00 | +1.2% | |
| Aug 11, 2017 | Fore Henrietta | Director | Buy | 6,000 | $23.99 | $143,932.20 | +33.3% | |
| Aug 11, 2017 | Whitesides George M | Director | Buy | 4,000 | $24.69 | $98,764.00 | New | |
| Mar 7, 2017 | Haumann Brett K | SVP Clin Dev &Chief Med Ofc | Sell | 14,000 | $31.50 | $440,974.72 | -4.1% | |
| Mar 3, 2017 | Shafer Bradford J | EVP, Gen. Counsel, Secretary | Sell | 26,829 | $31.86 | $854,771.94 | -14.2% | |
| Aug 25, 2016 | Haumann Brett K | SVP Clin Dev &Chief Med Ofc | Sell | 4,491 | $27.99 | $125,703.09 | -2.3% | |
| Aug 22, 2016 | Shafer Bradford J | EVP, Gen. Counsel, Secretary | Sell | 49,122 | $27.46 | $1,348,897.98 | -6.8% | |
| Aug 19, 2016 | Haumann Brett K | SVP Clin Dev &Chief Med Ofc | Sell | 9,509 | $27.97 | $265,966.73 | -4.6% |